Drug Profile
Levodopa/carbidopa intraduodenal - AbbVie
Alternative Names: ABT-SLV187; Carbidopa/levodopa enteral suspension; Carbidopa/levodopa intraduodenal; Duodopa; Duopa; LCIG; Levodopa/carbidopa intestinal gelLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator NeoPharma
- Developer AbbVie
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 02 Jan 2023 Launched for Parkinson's disease (Late-stage disease) in New Zealand (Intraduodenal) (Prior to December 2022)
- 02 Jan 2023 Registered for Parkinson's disease (Late-stage disease) in New Zealand (Intraduodenal) (Prior to December 2022)
- 29 Oct 2021 AbbVie completes phase III trial for Parkinson's disease in Australia, Canada, Czech Republic, England, Israel, New Zealand, Poland, Portugal, Russia, Thailand, United Kingdom, USA (Intraduodenal, Gel) (EudraCT2008-001329-33) (NCT00660673)